15-Deoxyspergualin "rescue therapy" for methylprednisolone-resistant rejection of renal transplants as compared with anti-T cell monoclonal antibody (OKT3)
- PMID: 8456469
- DOI: 10.1097/00007890-199303000-00010
15-Deoxyspergualin "rescue therapy" for methylprednisolone-resistant rejection of renal transplants as compared with anti-T cell monoclonal antibody (OKT3)
Abstract
A randomized trial with OKT3, an anti-T cell monoclonal antibody or with 15-deoxyspergualin against methylprednisolone-resistant rejection crisis was performed in 25 posttransplant patients immunosuppressed with prednisolone and cyclosporine. At least temporary reversal of rejection was observed in 58.3% of patients treated with 15-deoxyspergualin. This reversal rate may be quite comparable to 61.5% seen in patients treated with OKT3. Adverse effects with 15-deoxyspergualin were related to bone marrow suppression, while those with OKT3 were pyrexia, gastrointestinal symptoms, and herpes infection. In contrast to OKT3, which may act by modulating T cell surface antigen, 15-deoxyspergualin may be effective somewhere in the later stages of the rejection cascade.
Similar articles
-
Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center.Transplant Proc. 1999 Nov;31(7):2870-1. doi: 10.1016/s0041-1345(99)00596-5. Transplant Proc. 1999. PMID: 10578320 No abstract available.
-
Effectiveness of short-term OKT3 therapy in the treatment of steroid-resistant renal allograft rejection.Transplant Proc. 1998 Sep;30(6):2876-7. doi: 10.1016/s0041-1345(98)00851-3. Transplant Proc. 1998. PMID: 9745607 Clinical Trial. No abstract available.
-
OKT3 versus methylprednisolone for primary treatment of rejection: a retrospective evaluation.Transplant Proc. 2001 May;33(3):2196-7. doi: 10.1016/s0041-1345(01)01940-6. Transplant Proc. 2001. PMID: 11377501 No abstract available.
-
Monoclonal antibodies in renal transplantation: a review.Transpl Int. 1992 Sep;5(4):234-46. doi: 10.1007/BF00336077. Transpl Int. 1992. PMID: 1418316 Review.
-
Immunosuppressive mechanisms and action of deoxyspergualin in experimental and clinical studies. Japanese Collaborative Transplant Study Group of NKT-01.Transplant Proc. 1995 Feb;27(1):31-2. Transplant Proc. 1995. PMID: 7879015 Review. No abstract available.
Cited by
-
Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy.Clin Exp Nephrol. 2006 Mar;10(1):40-54. doi: 10.1007/s10157-005-0396-1. Clin Exp Nephrol. 2006. PMID: 16544177 Clinical Trial.
-
Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study.Arthritis Res Ther. 2011 Mar 1;13(2):R36. doi: 10.1186/ar3268. Arthritis Res Ther. 2011. PMID: 21356124 Free PMC article. Clinical Trial.
-
Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.Cochrane Database Syst Rev. 2017 Jul 20;7(7):CD004756. doi: 10.1002/14651858.CD004756.pub4. Cochrane Database Syst Rev. 2017. PMID: 28731207 Free PMC article.
-
Heat shock protein 70 (hsp70) as an emerging drug target.J Med Chem. 2010 Jun 24;53(12):4585-602. doi: 10.1021/jm100054f. J Med Chem. 2010. PMID: 20334364 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical